Implantation of a Novel Allogeneic Mesenchymal Precursor Cell Type in Patients with Ischemic Cardiomyopathy Undergoing Coronary Artery Bypass Grafting: an Open Label Phase IIa Trial
- 1.3k Downloads
Heart failure is a life-limiting condition affecting over 40 million patients worldwide. Ischemic cardiomyopathy (ICM) is the most common cause. This study investigates in situ cardiac regeneration utilizing precision delivery of a novel mesenchymal precursor cell type (iMP) during coronary artery bypass surgery (CABG) in patients with ischemic cardiomyopathy (LVEF < 40 %). The phase IIa safety study was designed to enroll 11 patients. Preoperative scintigraphy imaging (SPECT) was used to identify hibernating myocardium not suitable for conventional myocardial revascularization for iMP implantation. iMP cells were implanted intramyocardially in predefined viable peri-infarct areas that showed poor perfusion, which could not be grafted due to poor target vessel quality. Postoperatively, SPECT was then used to identify changes in scar area. Intramyocardial implantation of iMP cells with CABG was safe with preliminary evidence of efficacy of improved myocardial contractility and perfusion of nonrevascularized territories resulting in a significant reduction in left ventricular scar area at 12 months after treatment. Clinical improvement was associated with a significant improvement in quality of life at 6 months posttreatment in all patients. The results suggest the potential for in situ myocardial regeneration in ischemic heart failure by delivery of iMP cells.
KeywordsIschemic cardiomyopathy Coronary artery bypass grafting Stem cells Allogeneic Mesenchymal Heart failure
Coronary artery bypass grafting
Institutional review board
Limulus amebocyte lysate
Left ventricular ejection fraction
Major adverse cardiac and cerebrovascular events
Major histocompatibility class
Minnesota Living with Heart Failure Questionnaire
Mesenchymal stem cells
New York Heart Association
Polymerase chain reaction
Single photon emission computed tomography
Tissue inhibitor of matrix metalloproteinase
We would like to thank the molecular biologist Dr Nancy Piouka for her valuable contribution in the preparation and handling of the iMP cells.
Compliance with Ethical Standards
Sources of Funding
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
AR, MJE, and SS hold shares in Cell Therapy Limited.
Informed consent was obtained from all individual participants included in the study.
- 1.Braunwald, E. (2013). Heart failure. Journal of the American College of Cardiology Heart Failure, 1, 1–20.Google Scholar
- 3.Ammar, K. A., Jacobsen, S. J., Mahoney, D. W., et al. (2007). Heart failure prevalence and prognostic significance of heart failure stages. Application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation, 115, 1563–1570.CrossRefPubMedGoogle Scholar
- 12.Hillis, L. D., Smith, P. K., Anderson, J. L., et al. (2011). American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; Society of Cardiovascular Anesthesiologists; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. Journal of the American College of Cardiology, 58, e123–e210.CrossRefPubMedGoogle Scholar
- 15.Houtgraaf, J. H., de Jong, R., Kazemi, K., et al. (2013). Intracoronary infusion of allogeneic mesenchymal precursor cells directly after experimental acute myocardial infarction reduces infarct size, abrogates adverse remodeling, and improves cardiac function. Circulation Research, 113, 153–166.CrossRefPubMedGoogle Scholar
- 18.Perin, E. C., Willerson, J. T., Pepine, C. J., et al. (2012). Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA, 307, 1717–1726.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Hare, J. M., Fishman, J. E., Gerstenblith, G., et al. (2012). Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA, 308, 2369–2379.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Karantalis, V., DiFede, D. L., Gerstenblith, G., et al. (2014). Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: the prospective randomized study of mesenchymal stem cell therapy in patients undergoing cardiac surgery (PROMETHEUS) trial. Circulation Research, 114, 1302–1310.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Donndorf, P., Kaminski, A., Tiedemann, G., Kundt, G., & Steinhoff, G. (2012). Validating intramyocardial bone marrow stem cell therapy in combination with coronary artery bypass grafting, the PERFECT phase III randomized multicenter trial: study protocol for a randomized controlled trial. Trials, 13, 99.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Franchi, F., Ezenekwe, A., Wellkamp, L., Peterson, K. M., Lerman, A., & Rodriguez-Porcel, M. (2014). Renin inhibition improves the survival of mesenchymal stromal cells in a mouse model of myocardial infarction. Journal of Cardiovascular Translational Research, 7, 560–569.CrossRefPubMedGoogle Scholar